NGNE — Neurogene Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1404644 ·
Last close
$26.40
Market Cap
$528.30M
52W High
$43.66
52W Low
$15.93
ADV30
297,858
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -36,670,000 | -34,488,000 | 244,364,000 | 112,485,000 | 27,231,000 |
| Mar 2026 | 0 | — | -33,349,000 | -30,934,000 | 263,141,000 | 124,161,000 | 25,358,000 |
| Dec 2025 | 0 | — | -27,529,000 | -24,735,000 | 288,604,000 | 103,845,000 | 23,717,000 |
| Sep 2025 | 0 | — | -23,798,000 | -20,953,000 | 287,832,000 | 71,005,000 | 22,292,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-82,518,000
Investing CF
$105,289,000
Financing CF
$30,619,000
CapEx
$-684,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.51
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-383,583,000
Inventory
—
Receivables
$250,000
ST Investments
$119,021,000
EBIT TTM
$-98,635,000
Pretax Income TTM
$-98,638,000
Interest Exp TTM
$3,000
Analysts
7
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -103,328,000 | -90,351,000 | 288,604,000 | 23,717,000 | 264,887,000 | -77,173,000 |
| Dec 2024 | 925,000 | -82,605,000 | -75,144,000 | 335,730,000 | 25,355,000 | 310,375,000 | -70,603,000 |
| Dec 2023 | 0 | -55,583,000 | -36,317,000 | 222,573,000 | 36,549,000 | 186,024,000 | -51,422,000 |
| Dec 2022 | 0 | -56,517,000 | -55,189,000 | 109,265,000 | 255,004,000 | -145,739,000 | -52,824,000 |
TTM Snapshot
Revenues TTM
$-945,000
NetIncome TTM
$-98,638,000
OpCashFlow TTM
—
Assets (Latest)
$263,141,000
Forward EPS
$-5.18
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $35.00 · spot: $26.40 · call volume: 106 · put volume: 43Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MNPR | Monopar Therapeutics | $529.99M | $78.96 | — |
| DRUG | BRIGHT MINDS BIOSCIENCES INC. | $530.34M | $54.05 | — |
| PBYI | PUMA BIOTECHNOLOGY, INC. | $531.17M | $10.29 | — |
| IMMP | IMMUTEP Ltd | $534.96M | $3.63 | — |
| EVO | Evotec SE | $543.75M | $1.53 | — |
News headlines (Yahoo Finance, 1h cache)
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-05 20:01 · Yahoo
Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 11:30 · Yahoo
Neurogene Inc. Announces Pricing of $125 Million Public Offering
2026-07-01 11:00 · Yahoo
Neurogene Inc. Announces Proposed Public Offering
2026-06-30 20:01 · Yahoo
We Think Neurogene (NASDAQ:NGNE) Can Afford To Drive Business Growth
2026-05-05 11:37 · Yahoo
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
2026-06-29 11:00 · Yahoo
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
2026-08-11 11:30 · Yahoo
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
2026-06-08 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.